Navigation Links
Convoy Therapeutics Granted Patent for Proprietary SPACE Technology
Date:9/25/2013

Oro Valley, AZ (PRWEB) September 25, 2013

Convoy Therapeutics, Inc. is proud to announce that the United States Patent and Trademark Office has granted a patent for the proprietary Skin Permeating And Cell Entering (SPACE) Peptide technology. The company obtained a worldwide exclusive license to in 2011 from University of California at Santa Barbara.

“The granting of this patent furthers the advancement of our technology and its many uses in the field,” states Dr. John Muraski, President and CEO of Convoy Therapeutics and its parent company ACTUS Biotechnologies, Inc. The company is currently working with a number of cosmetic and pharmaceutical partners to take advantage of its platform technology with a variety of molecules. Furthermore, Dr. Muraski states, “Our platform can be adapted to various active ingredients to enable penetration of large molecules past the outer layer of the skin and into the epidermis and dermis, and there is evidence that it can also enhance retention of some small molecules.” The recent addition of a team of professionals with substantial experience in the dermatology industry has expanded the capabilities of the company as they seek to market two reformulations in the coming 12-36 months: a high molecular weight topical Hyaluronic Acid cosmetic for the reduction of fine lines and wrinkles and Cyclopsorb™, a topical cyclosporine for the treatment of moderate to severe psoriasis.

The company’s Topical Hyaluronic Acid is a cosmetic application intended to maintain a smooth complexion between filler or toxin injections while being passively absorbed into the skin, reaching the epidermal and dermal layers. Convoy is currently completing safety studies and scale up. The company has an expected launch date for their Topical Hyaluronic Acid product in Q3, 2014.

Convoy’s second product, Cyclopsorb™, for the topical treatment of moderate to severe psoriasis, is currently in the final stages of formulation to optimize long-term stability for scale up and completion of non-clinical toxicology. With written confirmation from the FDA that the 505(b)(2) pathway is appropriate for this product, the company anticipates a market launch in Q3, 2016.

The Convoy delivery platform represents a major leap forward in the topical delivery of active compounds. Convoy’s platform can potentially be used in dermatological products for the treatment of skin cancers, skin care and cosmetics, cosmeceuticals, and the reformulation of existing molecules for better penetration and retention in the skin.

Convoy Therapeutics is a subsidiary of the ACTUS Biotechnologies accelerator, an organization dedicated to accelerating innovative novel technologies to commercialization. The company was founded in 2011 based upon technology originally developed by Dr. Samir Mitragotri and his laboratory at the University of California Santa Barbara. More information can be found at http://www.convoytx.com. Information about ACTUS Biotechnologies can be found at http://www.actusbiotech.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11156464.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
2. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
3. Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
4. Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013
5. Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard
6. PTC Therapeutics to Present at European Pediatric Neurology Society Congress
7. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
8. Adheron Therapeutics Names New Senior Leadership
9. Case Report Suggests Microbiome Therapeutics NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
10. Echo Therapeutics Sends Response to Shareholder Letter
11. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on ... of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ... is expected to deliver therapeutic levels of olanzapine for a period of 3 months., ...
(Date:2/24/2017)... SAN DIEGO , Feb. 24, 2017  Aethlon ... the following note authored by its Chairman and CEO, ... address at the Munich Security Conference last Saturday, ... engineered virus could kill more people than nuclear weapons. ... by U.S. and U.K. intelligence agencies, that scientific terrorists ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell ... unaudited financial results for the third quarter and first ... 2016. Third Quarter of Fiscal 2017 Highlights ... fiscal 2017 increased by 18.6% to RMB200.9 million ($28.9 ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
Breaking Biology Technology:
(Date:2/9/2017)... , Feb. 9, 2017 The biomass boiler ... of the biomass boiler market globally in terms of ... biomass boilers. The market for biomass boilers has been ... end-user, application, and country/region. The market based on feedstock ... forest residues, biogas & energy crops, urban residues, and ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 The ... largely by the confluence of organizations, desires to ... for knowledge-based systems (password and challenge questions), biometrics ... and government systems. The market is driven by ... demarcation between consumer and enterprise uses cases, with ...
Breaking Biology News(10 mins):